Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
SAFETY RUN-IN: Has received a live vaccine within 30 days prior to the first dose of trial treatment
RANDOMIZED PHASE II CLINICAL TRIAL: Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial drug.
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Live vaccine within 4 weeks of the first dose of pembrolizumab and while on trial is prohibited
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Have received a live vaccine within 30 days prior to the first dose of trial treatment.
Received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Subject has received a live vaccine within 30 days prior to the first dose of trial treatment
Have received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment.
Is known to have received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
The participant has received a live vaccine within 30 days prior to the first dose of trial treatment.
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Patients who have received a live vaccine within 30 days prior to the first dose of trial treatment.
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
